AI-generated · cited to primary sources · not investment advice
Max Healthcare (543220) Aug 2025 Filing Analysis
Does management do what it says?
The divestment of the Chitta and Anoopshahr hospitals (part of the Jaypee acquisition) was completed effectively on September 18, 2025. (2 met across 2 tracked commitments)
“ROCE threshold levels of 20-25% within 4 years post acquisition”
Completion of 100-bed project at Max Nagpur. — target: 100 beds
“100 beds at Max Nagpur – We are currently awaiting formal environmental clearance... we expect to complete the project within 24 months.”
See the full cited Management analysis of Max Healthcare
How durable is the business?
The core hospital business continues to expand rapidly, driven by the integration of recent acquisitions (Lucknow, Nagpur, Noida) and the launch of Dwarka. Gross revenue grew 27% YoY, significantly outpacing the previous 10% growth rate. (5 expanding)
“Network gross revenue was Rs. 2,574 crores, up from Rs. 2,028 crores in Q1 last year... This reflects an increase of 27% year-on-year”
The clinical moat is being strengthened through the addition of advanced oncology services (radiation therapy) in units that previously lacked them, such as Dwarka and Lucknow, which is expected to drive higher ARPOB. (3 expanding, 1 shifted)
“some of the newer hospitals, particularly Dwarka and Lucknow, do not offer radiation oncology at this point... in the third quarter, we are expecting the bunkers to come through... you will see a larger share of oncology certainly in these hospitals”
International patient revenue showed strong momentum, growing 32% YoY. This segment's contribution to total revenue is increasing as the company opens direct-to-fly offices and focuses on international marketing. (2 expanding, 1 stable)
“International patient revenue reached Rs. 208 crores, registering a growth of 32% year-on-year”
The company is divesting non-core assets (Chitta and Anoopshahr) to focus resources on its high-performing 'cluster' geographies, further refining its scale advantage in key markets. (2 shifted, 1 expanding)
“As part of our strategy to focus on super-specialty care in selected geographies, we have executed a binding term sheet to divest Chitta and Anoopshahr hospitals”
See the full cited Business Model analysis of Max Healthcare
Where does growth come from?
International revenue growth is accelerating significantly, reaching 32% YoY growth this quarter despite geopolitical challenges, driven by direct-to-fly marketing offices. (5 accelerating across 5 signals)
“International patient revenue reached Rs. 208 crores, registering a growth of 32% year-on-year... despite airspace restrictions and geopolitical volatility.”
See the full cited Future Growth analysis of Max Healthcare
What could break the thesis?
Concentration remains high with 3,900+ beds in Delhi NCR & Mumbai. However, the company is diversifying into Nagpur, Lucknow, and Pune to mitigate regional risk. (4 stable, 1 easing)
“Max Healthcare has 3,900+ beds in Delhi NCR & Mumbai – highest proportion compared to peers”
See the full cited Risk analysis of Max Healthcare
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.